The SCORE2 Comparison of Treat-and-Extend vs Monthly Anti–Vascular Endothelial Growth Factor Dosing

The SCORE2 Comparison of Treat-and-Extend vs Monthly Anti–Vascular Endothelial Growth Factor... Research Original Investigation Monthly vs Treat-and-Extend Anti-VEGF Regimens for Macular Edema Invited Commentary The SCORE2 Comparison of Treat-and-Extend vs Monthly Anti–Vascular Endothelial Growth Factor Dosing Short-term Similarities and Longer-term Questions Jennifer K. Sun, MD, MPH Therapy with anti–vascular endothelial growth factor (anti- cept and bevacizumab groups received statistically signifi- VEGF) agents has dramatically improved visual outcomes for cantly fewer injections on average (2 and 1.3 fewer injections, respectively), the clinical relevance of this point estimate of a patients with various retinal vascular diseases, including reti- nal vascular occlusion, diabetic macular edema, and neovas- 0.7-injection difference between groups over 6 months is un- cular age-related macular de- known. As might be expected in this short-duration, mod- generation. Landmark phase estly sized study, there were no differences in the safety pro- 3 randomized clinical trials file that were identified between the treatment groups. These Related article page 337 comparing anti-VEGF alter- results may be helpful to clinicians who are trying to choose natives have answered key questions regarding their compara- between treatment strategies by providing evidence that a TAE 1-3 tive effectiveness in these diseases. However, a remaining treatment strategy reduces the numbers of burdensome in- issue that faces physicians is http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

The SCORE2 Comparison of Treat-and-Extend vs Monthly Anti–Vascular Endothelial Growth Factor Dosing

Preview Only
2 pages

Loading next page...
 
/lp/jama/the-score2-comparison-of-treat-and-extend-vs-monthly-anti-vascular-i0SThLd774
Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2168-6165
eISSN
2168-6173
D.O.I.
10.1001/jamaophthalmol.2017.6855
Publisher site
See Article on Publisher Site

Abstract

Research Original Investigation Monthly vs Treat-and-Extend Anti-VEGF Regimens for Macular Edema Invited Commentary The SCORE2 Comparison of Treat-and-Extend vs Monthly Anti–Vascular Endothelial Growth Factor Dosing Short-term Similarities and Longer-term Questions Jennifer K. Sun, MD, MPH Therapy with anti–vascular endothelial growth factor (anti- cept and bevacizumab groups received statistically signifi- VEGF) agents has dramatically improved visual outcomes for cantly fewer injections on average (2 and 1.3 fewer injections, respectively), the clinical relevance of this point estimate of a patients with various retinal vascular diseases, including reti- nal vascular occlusion, diabetic macular edema, and neovas- 0.7-injection difference between groups over 6 months is un- cular age-related macular de- known. As might be expected in this short-duration, mod- generation. Landmark phase estly sized study, there were no differences in the safety pro- 3 randomized clinical trials file that were identified between the treatment groups. These Related article page 337 comparing anti-VEGF alter- results may be helpful to clinicians who are trying to choose natives have answered key questions regarding their compara- between treatment strategies by providing evidence that a TAE 1-3 tive effectiveness in these diseases. However, a remaining treatment strategy reduces the numbers of burdensome in- issue that faces physicians is

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Apr 24, 2018

References

Sorry, we don’t have permission to share this article on DeepDyve,
but here are related articles that you can start reading right now:

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off